Pharmaceutical Stock Jumps After Key Trial Findings

By: Dylan Sikes – AllPennyStocks.com News

Wednesday, April 16, 2025

A pharmaceuticals company based out of Maryland is turning heads on Wednesday after the company announced that data demonstrated the potential efficacy of its oral ketamine analog, Ketamir-2, in treating diabetic neuropathy in animal model, according to a press release from this morning.

Traders wasted little time buying up shares of MIRA Pharmaceuticals Inc. (Nasdaq:MIRA), thrusting the micro cap up to $1.33/share (+48.24%) at the early session high. This move could indicate a breakout is imminent as this stock fights to breakout of a multi-month downtrend.

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.